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Abstract 
There is increasing evidence that the growing rate of chronic diseases in China is 
related to the transitions that the country is undergoing. This project will review the 
prevalence of chronic disease in China and make a case for how multinational 
pharmaceutical companies can position themselves to provide pharmaceutical drugs that 
prevent or treat chronic diseases. Worldwide chronic diseases, various types of chronic 
diseases, the risk factors, underlying determinants, and the increasing rate of chronic 
diseases in China will be discussed. The paper will also analyze China’s healthcare 
system and give a better understanding of what condition the system is in to serve the 
needs of the people. A review of the forces within China’s pharmaceutical industry will 
give a better insight for how multinational pharmaceutical corporations can penetrate into 
this market and establish operations. Recommendations are also made for how China can 
reduce chronic diseases via government polices, community based programs, and 
pharmaceutical interventions. 
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1: Introduction 
 China is undergoing a social, economic, and nutritional transition, and the result 
is a significant change in the social environments and lifestyles of people (Liu, 2008). 
China is becoming wealthier; however, the country faces public health risks and a 
growing prevalence of chronic diseases. Spending on healthcare has not kept up in pace 
with the economic growth that China has achieved (Liu, 2008). There are a rising number 
of middle class families with improved healthcare access that are more educated and 
aware of the benefits of Western drugs. The Chinese pharmaceutical industry is 
becoming more consolidated, and stronger intellectual property rights and laws are being 
enforced by the Chinese government. The return of Western-educated Chinese with 
technical and management skills can help market drugs and establish multinational 
corporations (Greene, 2006).  
1.1 Objective and scope of paper 
There is a rising rate of chronic disease in China that is closely related to China’s 
transition towards social reform, improved economics, less physical activity, and high fat, 
low nutrition diets. This paper looks at the changes in China’s healthcare system and 
pharmaceutical industry, and examines what condition the healthcare system is in to 
serve the needs of the people. It makes a case for how multinational pharmaceutical 
companies can help fill the need for pharmaceutical drugs that prevent or treat chronic 
diseases. Additionally, a review of the forces within China’s pharmaceutical industry will 
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provide insight into how multinational pharmaceutical corporations could penetrate into 
this market and establish operations. This paper also looks at chronic diseases in China 
and worldwide, various types, risk factors, and underlying determinants.  It also makes 
recommendations on how China can help reduce the rate of chronic diseases through 
programs and pharmaceutical intervention.  
1.2 Understanding worldwide chronic disease  
The following subsections discuss worldwide chronic diseases.  The first 
subsections examine various types of chronic diseases, risk factors, and underlying 
determinants.  The final subsection looks at consequences on health due to risk factors 
and access to healthcare. 
1.2.1 Various types of chronic diseases 
The World Health Organization (WHO) tells us that there are different names in 
different contexts for chronic diseases. The term ‘non-communicable’ disease, they say, 
is used in place of chronic disease to differentiate it from ‘communicable’ diseases that 
are infectious. There are many different types of chronic diseases.  The most prevalent 
ones include cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes. 
Figure 1:1 below shows the projected main causes of death worldwide for all ages in 
2005. Nearly 30% of the worldwide deaths were a result of communicable diseases, 
maternal conditions, perinatal conditions, and nutritional deficiencies. Cardiovascular 
disease, cancer, chronic respiratory diseases, diabetes, other chronic diseases, and injuries 
accounted for the remaining 70% of deaths. Chronic disease epidemics can take decades 
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to develop, normally originating during childhood. With a long period needed for 
development, there are opportunities for people to find ways to prevent these diseases 
from worsening, usually through long-term treatments.  
Figure 1:1 Projected main causes of death, worldwide, all ages, 2005 
 
(Source: WHO, 2005) 
 A general assumption is that chronic disease-related deaths occur to the elderly. 
This is a misconception as approximately 16 million chronic disease-related deaths occur 
each year to those who are 70 years or younger. A more alarming fact is that nearly 80% 
of chronic disease deaths occur at earlier ages in low and middle-income countries 
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compared to higher income countries (WHO, 2005). These low and middle-income 
countries account for most of the world’s population (WHO, 2005).  Yach et al., (2004) 
expect the rate of occurrence for chronic diseases in these developing countries to 
increase substantially in the next two decades. Figure 1:2 shows the projected main 
causes of death by the World Bank Income group for all ages in 2005.  
Figure 1:2 Projected main causes of death, all ages, by World Bank Income group, 2005 
 
 
(Source: WHO, 2005) 
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1.2.2 Risk factors and underlying determinants 
  The risk factors for chronic disease are the same for men and women in the 
varying regions. The most important modifiable risk factors include an unhealthy diet 
rich in high calorie foods, physical inactivity, use of tobacco, and alcohol abuse (Yach et 
al., 2004). These factors tend to cause an increase in blood glucose levels and shifts in 
blood lipids, which leads to an individual becoming overweight and obese. The current 
burden of chronic diseases reflects past exposure to risk factors, while current exposures 
determine the future burden of chronic diseases (Yach et al., 2004).  
 
 Underlying causes that aid the risk factors are more complex and are related to 
social, economic, and cultural changes due to global marketing of multinational 
corporations, trade and agricultural policies, urbanization, ageing populations, changes in 
living and working patterns, and the environment (Mohindra, 2007). Revolutionary 
changes in transportation, advertising, and food production have worked to alter lifestyles 
abruptly in many developing countries (Birt, 2006). Popular Western junk foods, cheap 
cigarettes, and automobiles has resulted in many citizens of poor countries eating worse 
and exercising less than they did a decade ago (Birt, 2006). The WHO (2005) states that 
globalization drives chronic disease population risks both directly and indirectly. There 
are health related advantages to globalization, such as the technological advancements in 
medical information and communication transfers used by health care systems (WHO, 
2005). However, there are some negative health related effects from globalization as 
well. These negative effects are the result of a nutrition transition. People in low and 
middle-income countries are now consuming diets that are high in animal fats, trans fats, 
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salt, and sugar. The reason for this nutritional transition is that the demands for goods 
high in fats, salt, and sugar have risen. Public health awareness in these developing 
countries has not caught up to this new level of affluence (Birt, 2006).  Populations in 
these low and middle-income countries are moving from the countryside to urban areas to 
earn higher incomes, and this results in reduced time to prepare food themselves (Birt, 
2006). The supply of such processed foods has also increased in terms of production, 
promotion, and marketing.  
 
  The marketing of tobacco and other products that have adverse health effects has 
increased (WHO, 2005).  As economic development occurs, tobacco use and obesity also 
increases (Yach et al., 2004). The uptake of risk factors eventually leads to the onset of 
diseases. Yach et al. (2004) notes that, in the absence of policy actions, consumption of 
tobacco, alcohol, and foods high in fat and sugar increases along with gross national 
product.  This is followed decades later by associated increases in chronic diseases. 
Chronic disease rates generally do not decrease until the nation achieves high levels of 
wealth and literacy, whereupon governments are more likely to respond to public health 
concerns using a broad range of policy instruments to influence consumption trends 
(Yach et al., 2004).  
 
  Global marketing targeted at children has reached epidemic proportions 
worldwide, and it has lead to an increase in unhealthy nutrition. The world populations 
are becoming unhealthy consumers of products such as caffeine and other drugs at an 
increasingly young age (Veracity, 2006). According to a study published in the Journal of 
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American Medical Association (JAMA) in 1991, almost all 6 year olds living in the 
United States could identify Joe Camel.  This makes Joe Camel as recognizable to 
children as Mickey Mouse (Veracity, 2006). Corporations also market products such as 
soft drinks, which are a major source for sugar and caffeine, to children and adults. About 
one fifth of American one and two year olds drink soda, consuming a potentially 
dangerous stimulant and large doses of sugar before they are capable of consuming many 
adult foods (Veracity, 2006).  
 
  Body mass index levels and the total cholesterol increases in poor countries when 
personal incomes increase and the nations become wealthier.  Increase in wealth and 
urbanization affects the rate of increase for chronic disease. Urbanization results in 
people being exposed to new products, technologies, unhealthy goods, and adoption of 
less physical activity (WHO, 2005). The type of general policy environment is also a 
determinant of people’s health. Those in environments that have supportive systems for 
food, agriculture, trade, media advertising, transport, urban design, and the built 
environment allow people to make well-informed, healthier choices (WHO, 2005). Those 
environments that are unsupportive, especially those in low income or deprived areas, do 
not provide the population with the opportunity to benefit from the existing knowledge 
on causes and preventative measures for chronic diseases (WHO, 2005). The life 
expectancy is usually shorter and most diseases are more common further down the 
social ladder in most societies (ICHS, 2003). Those who are further down in the social 
ladder usually run at least twice the risk of serious illness and premature death compared 
to those who are at the top of the social ladder (ICHS, 2003).  
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1.2.3 Consequences on health due to risk factors  
Chronic disease risk factors are a leading cause of death and disease burden 
throughout the world. The status or economic development of a country does not matter. 
According to WHO (2005), the leading risk factor globally is raised blood pressure, 
followed by tobacco use, raised total cholesterol, and low fruit and vegetable 
consumption. The major risk factors together, they say, account for around 80% of deaths 
from heart disease and stroke. Table 1:1 describes an approximate number of people that 
die each year from various risk factors such as tobacco, physical inactivity, obesity, high 
blood pressure, and high cholesterol. Nearly 24 million people die each year from these 
risk factors; however, the number would be even higher if one considers all risk factors.  
Table 1:1 Death tolls from risk factors 
Each year at least: 
4.9 million people die as a result of tobacco use; 
1.9 million people die as a result of physical inactivity; 
2.7 million people die as a result of low fruit and vegetable consumption; 
2.6 million people die as a result of being overweight or obese; 
7.1 million people die as a result of raised blood pressure; 
4.4 million people die as a result of raised total cholesterol levels 
(Source: WHO, 2005) 
 WHO estimated in 2005 that there were over 1 billion people globally that were 
overweight and over 300 million that were obese. If the current trends continue, it is 
estimated that by 2015 the total number of humans that will be either overweight or obese 
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will rise to 1.5 billion (WHO, 2005). Regardless of income levels, it is projected that 
there will be a rise in the average body mass index for men and women. The largest of 
these increases is projected to be for women in upper middle-income countries. This 
group of women has already surpassed those women in the high-income countries 
(WHO, 2005).  
WHO expects the number of deaths from chronic disease to increase from 2005 to 
2015.  However, death from communicable diseases, maternal conditions, prenatal 
conditions, and nutritional deficiencies should decrease. This projected increase in death 
related to chronic disease is driven primarily by the ageing population and those 
populations that are now exposed to the risk factors associated with chronic diseases. It is 
approximated that there will be a total of 64 million deaths in 2015. Of the 64 million, 17 
million will die from communicable diseases, maternal or paternal complications, or 
nutritional deficiencies. Additionally, 41 million people in 2015 will die from non-
communicable chronic diseases (WHO, 2005).  
1.2.4 Access to healthcare 
The lack of access to quality healthcare such as diagnostic and clinical prevention 
services due to social and economic inequalities adds to the burden of chronic diseases. 
Low income and the poor have barriers to healthcare services.  These include economic 
constraints, over priced drugs, means of transportation to healthcare centres, and poor 
responsiveness from the healthcare centres (WHO, 2005).  Financial constraints and the 
inability to afford out of pocket healthcare charges contribute to the increasing number of 
people suffering and dying from chronic diseases. Dispersed healthcare centres in 
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developing countries results in high transport costs that many cannot afford.  The lack of 
pharmacies and access to prescription drugs is a factor, and rural healthcare centres offer 
services that also might be lower quality than in urban centres. Even in countries such as 
South Africa where prescription drugs are subsidized or provided for free by the 
government to the low and middle-income people, the wealthier population is twice as 
likely to have received treatment compared to those who are poor (WHO, 2005). 
Communication and cultural barriers also affect the type and quality of healthcare 
services and treatment these people receive.  
1.3 The economic impact of chronic diseases 
Chronic diseases affect the national economy of a country in direct, indirect, and 
intangible ways. The direct costs are the costs of medical care, which includes 
prevention, diagnosis, and treatment of the diseases (Suhrcke et al., 2006). Medical 
expenses incurred from these diseases results in reduced income for families, which 
affects other investments including the education of children. Expenditure on addictive 
products such as tobacco and alcohol are costly to poor households. The poor tend to 
spend a disproportionate amount of their income on tobacco and alcohol, potentially 
substituting for food purchases or investment in human capital such as health and 
education (Suhrcke et al., 2006). Studies conducted in Bangladesh in the 1990s found that 
on average people spent twice as much on cigarettes as they did on housing, clothing, 
health and education combined. The poorest households spent close to 10 times as much 
on tobacco as they did on education (Suhrcke et al., 2006).  
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The indirect costs of chronic diseases are realized through the loss of human 
resources and loss of productivity of labour due to ailment from chronic diseases 
(Suhrcke et al., 2006). Agricultural productivity, including critical activities such as 
timely planting of crops and harvesting may be delayed (WHO, 2005). Generally, 
healthier individuals can produce more output per hour worked thereby increasing labour 
productivity due to better physical and mental capacities (Suhrcke et al., 2006). In 
wealthy nations that are usually equipped with social insurance systems, evidence shows 
the negative labour market effects chronic diseases have on the national economy. It is 
reasonable to expect poor nations with underdeveloped and informal insurance system to 
experience a greater negative impact on their economy due to ill health and chronic 
diseases (Suhrcke et al., 2006).  
The intangible costs of chronic diseases are reflected in the psychological 
dimensions of illness that include pain, bereavement, anxiety, stress, and suffering 
(Suhrcke et al., 2006). These factors contribute to the reduced earning potential of 
families that culminates in reduced national income or gross domestic product (GDP) for 
the nation. Based on literature reviews, the cost of chronic disease and their risk factors is 
significant and sizeable, ranging from 0.02% to 6.77% of a country’s GDP (Suhrcke et 
al., 2006). Developing countries struggle between increasing the economic wealth trying 
to alleviate poverty and reducing social and health deprivations (Mohindra, 2007). The 
governments in poor countries face serious challenges in trying to develop public policies 
that serve the interests of the people. Limited resources especially during times of macro-
economic instability have forced these poorer nations to seek financial support from 
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international financial institutions such as the International Monetary Fund and the World 
Bank (Mohindra, 2007).  
 
Cost of illness and disease studies conducted in the United States can provide 
conceptual insight for other countries including developing countries for determining the 
effect risk factors have on driving healthcare costs (Suhrcke et al., 2006).  Pronk et al. 
(1999), found that healthier lifestyles, defined by physical activity times three times per 
week, a moderate BMI, and non-smoking reduced healthcare costs by 49% compared to 
an unhealthy lifestyle for adults 40 and older. Sturm (2002) analyzed the per person 
annual healthcare costs associated with being obese, overweight, smoking, and heavy 
alcohol consumption among working age US population. His research found that obesity 
increased a person’s annual healthcare cost by 36%, smoking increased cost by 21%, and 
heavy alcohol consumption increased cost by 10% (Strum, 2002). Further findings have 
found that healthcare costs associated with obesity are considerably large and have 
reached the costs of smoking and heavy drinking (Suhrcke et al., 2006).  
1.4  Summary  
In summary, there are different types of chronic diseases; chronic disease can be 
referred to as non-communicable diseases to differentiate it from communicable diseases, 
which are infectious. Approximately 30% of worldwide deaths were a result of 
communicable diseases, maternal and perinatal conditions, and nutritional deficiencies. 
Cardiovascular disease, cancer, chronic respiratory diseases, diabetes, other chronic 
diseases and injuries accounted for the remaining 70% of deaths.  
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The ageing population and populations that are transitioning to increased risk 
factor association drives a projected increase in chronic disease-related deaths.  Chronic 
diseases affect the national economy of a country in direct, indirect, and intangible ways.  
The direct costs are the costs of medical care, such as prevention, diagnosis, and 
treatment.  A country realizes the indirect costs through the loss of human resources and 
compromised productivity of labour due to ailment from chronic diseases. The intangible 
costs reflect the psychological dimensions of illness that include pain, bereavement, 
anxiety, stress, and suffering.   
 
These factors contribute to the reduced earning potential of families, and that 
culminates in reduced national income or gross domestic product (GDP) of the nation. 
Developing countries struggle between increasing the economic wealth, trying to 
alleviate poverty, and reducing social and health deprivations. The governments in poor 
countries face serious challenges in trying to develop public policies that serve the 
interests of their people.  
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2: Chronic diseases in China 
Since the 1950’s China has improved the level of sanitation, hygiene, and water 
quality.  They have increased vaccinations, improved medical care, and brought about 
increased social reforms. There have been advancements in universal education, higher 
incomes, better nutrition, and better housing (Yang et al., 2008). These changes, along 
with the one child policy, have shifted the age structure of the population and, as a result, 
fertility and mortality have declined, thereby increasing the proportion of elderly people 
(Yang et al., 2008). In 2000, China’s above 65-age category accounted for 7% of the 
entire population, and by 2040 it is estimated that this number will increase to 
approximately 20% of the entire population (Wang et al., 2005). 
 
 In addition to the ageing population, the shift towards more social reform has 
affected the rate of increase in chronic diseases in China. There has been a steady 
increase in the standard of living and the rate of urbanization. From 1990 to 2000, the 
proportion of people living in urban settings in China has increased from 26% to 36%.  
The number of cities in China and the number of townships has also increased (Wang et 
al., 2005). By 2010, urbanization is expected to reach 45%; by 2030, urbanization is 
expected to reach 60%; and by 2010, 200 million more people are expected to be living 
in urban areas. This growth comes at a cost to the healthiness of China’s population. 
There is a clear relationship between urbanization and the prevalence of diabetes in China 
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(Wang, et al., 2005). Figure 2:1 illustrates the increasing prevalence of individuals with 
diabetes in larger cities and those who have accumulated more wealth. Additionally, 
behavioural changes as a result of environmental change are occurring. These behaviour 
changes include changing diets, increased automobile usage, increased tobacco 
consumption, and decreasing levels of physical activity.  
Figure 2:1 Prevalence of diabetes in China, 2002 
 
(Source: Wang, et al., 2005) 
Table 2:1 is a summary of the costs to the Chinese economy in 1995 and the 
projected costs in 2020 of only diet-related non-communicable diseases. Annual 
healthcare costs of diet related non-communicable diseases in 1995 reached a staggering 
$11.74 billion dollars with productivity costs owing to premature death of approximately 
$3.41 billion (Popkin et al., 2001). The total cost as a percentage of the GDP as a result of 
the healthcare system and loss of productivity accounted for 2.1% in 1995.  
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Table 2:1 Summary of costs of diet-related noncommunicable diseases in China, 1995 
and 2025 
Type of Cost China 
Number of deaths/year owing to DR-NCDs: 1995 2.57 million 
Deaths owing to DR-NCDs as percentage of all deaths: 1995 41.6% 
Number of deaths/year owing to DR-NCDs: 2020 7.63 million 
Deaths owing to DR-NCDs as percentage of all deaths: 2020 52.0% 
Annual healthcare system costs of DR-NCDs: 1995 $11.74 billion 
Healthcare system costs DR-NCDs as percentage of all diseases: 1995 22.6% 
Healthcare system costs DR-NCDs as percentage of GDP: 1995 1.6% 
Productivity costs DR-NCDs owing to premature death: 1995 $3.41 billion 
Productivity costs as percentage of GDP: 1995 0.5% 
Total costs DR-NCDs (heath + productivity): 1995 $15.1 billion 
Total costs DR-NCDs as a percentage of GDP: 1995 2.1% 
(Source: Popkin et al., 2001) 
 
2.1 The nutritional transition 
The dietary structure, physical activity levels, obesity, and diet-related non-
communicable diseases are changing at a rapid pace throughout the emerging markets. 
China, with over 1.3 billion people as of 2008, is the largest populated nation in the world 
reflecting many of these changes (Popkin, 2001).  China has experienced increased 
urbanization in the past decade, but a large number of people remain in the rural areas. 
These two societies differ in their economic and nutritional transitions. However, the rate 
of occurrence of diet-related non-communicable diseases is quite similar (Popkin, 2001).  
Since the end of the Second World War, emerging markets such as India and 
China faced extreme poverty levels and hunger.  However, the recent shifts in the past 
decades towards improved economic gains have made China into one of the largest 
growing economies.  Between 1978 and 1997, they achieved the largest annual average 
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rate of growth for real gross domestic product (GDP) per capita of 8.5% (Popkin, 2001). 
This rate of growth has enabled the country to achieve improved living standards and to 
decrease the number of people living in poverty. Along with this growth, China has 
improved its supply network for securing food, which in turn has affected the dietary 
structure of the country (Popkin, 2001).  
It is important to consider that these economic shifts have not been consistent 
throughout all regions in China. There are large subpopulations that have been bypassed 
by progress. According to Barry Popkin (2001), some of the western and south central 
provinces of China face extensive poverty compared to the eastern provinces that appear 
to have much lower signs of economic deprivation. Popkin (2001) notes that, while the 
number of people living in poverty has decreased, an increasing disparity between 
incomes is emerging. Some population groups have seen a decrease in living standards 
because of changes in income or nutritional intake.  
  The people are consuming different type of foods in both the urban and rural 
areas. Research shows that half of the adults in China are consuming a high fat diet 
(Popkin, 2001). A larger consumption of rice and wheat has occurred in place of 
sorghum, barley, maize, and millet (Popkin, 2001). The diets of all income groups have 
shifted, with the greatest shifts seen in those in the urban locations and those with high 
incomes (Popkin, 2001). Lower income people are able to afford more fat from edible 
oils, resulting in an upward transition towards increased fat consumption. According to 
Popkin (2001), the income elasticity for the consumption of edible oils, pork, and eggs 
has increased significantly at all income values.  Additionally, the quantity of fat in the 
diet increases much more rapidly with increases in income. These changes in dietary 
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intake will lead to a deterioration of the overall healthiness of the people. This results in a 
trend towards an increase in obesity in China.  
2.2 Behavioural risk factors  
There has been a rapid increase in the adoption of a Western lifestyle that is more 
sedentary (Popkin, 2001). The transition in nutrition and activity level is a result of the 
shift in the economic structure of China. The economy has shifted from a preindustrial 
agrarian state to one that is more industrialized (Popkin, 2001b). The advancement and 
introduction of technologies has created more sedentary service sector occupations 
(Popkin, 2001). A growing number of those living in urban areas now work in offices or 
on assembly lines. These jobs require less physical activity and energy expenditure 
compared to the rigorous physical activity needed to work on farmland. Sedentary work 
combined with a high fat diet increases the body mass index and the risk of obesity 
(Popkin, 2001b). Another area that has caused significant changes in nutrition and the 
level of physical activity is an increase in television ownership. With increased incomes, 
large segments of poorer population can now afford television.  Television subjects 
viewers to various forms of persuasive marketing campaigns promoting high fat snacks, 
foods, and drink. Additionally, television watching has adversely affected the amount of 
time children spend actively playing as opposed to sitting motionless staring at a 
television.  The advent of video games has also reduced the amount of active playing 
time. According to Popkin (2001), of the total number of adults aged 25 to 45 years in 
eight provinces of China, 17.6% were overweight or obese in 1997. During the eight year 
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period of collecting data the proportion of overweight adults in this group for females 
doubled and almost tripled for the males (Popkin, 2001). 
2.3 Conditions in need of pharmaceutical drugs 
This subsection discusses some of the main conditions requiring pharmaceutical 
drugs for treatment.  These include hypertension, obesity, being overweight, diabetes, and 
tobacco usage.   
2.3.1 Hypertension 
Over the past 30 years, the number of people with hypertension has been steadily 
increasing in China.  In 2002, reports found that nearly 18% of the Chinese adults aged 
15 years and older had hypertension, which corresponds to 177 million people (Yang et 
al., 2008). One of the causative factors for hypertension is high salt intake. According to 
Yang et al (2008), in 2002, the average daily salt intake for a reference man (aged 18 
years with light level of physical activity) was 12 grams per day, which is approximately 
twice that recommended by Chinese dietary guidelines. Some rural areas had an intake of 
salt as high as 14.7 grams. Controlling hypertension by individuals is quite low, only 
30% of adults with hypertension are even aware of their condition. The need for 
pharmaceutical drugs specific for combating hypertension is high within China. Drugs for 
treatment, such as adrenergic inhibitors, peripheral agents, alpha-blockers, beta-blockers, 
direct vasodilators, and calcium antagonists will be needed for treatment.  
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2.3.2 Obesity and overweight people  
According to Yang et al. (2008), nearly 18.9% of Chinese adults over the age of 
18 were overweight in 2002, and nearly 3% were obese. There was an increase of 39% 
from 1992 to 2002 in the proportion of overweight adults (Yang et al., 2008). In 2002, the 
larger cities accounted for 13% of children and adolescents aged 7-17 years that were 
overweight while 8% were obese (Wang et al., 2005). Figure 2:2 illustrates the increasing 
proportion of obese and overweight children from those living in rural villages to those in 
larger cities.  
Figure 2:2 Percentage of children aged 7-17 years who were overweight and obese in        
China, 2002 
 
(Source: Wang, et al., 2005) 
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One significant factor to consider in terms of obesity and overweight people in 
China is that over 20 years from 1982 to 2002 the caloric intake has changed very little. 
The approximate intake has remained at about 2491-2250 Kcal per day. This indicates 
that the increase in weight is due to a change in the type of foods and, more importantly, 
reduced physical activity (Yang et al., 2008). The average time spent watching television 
is increasing and only 15% of urban Chinese adults exercised regularly in 2002 (Yang et 
al., 2008). Pharmacological drugs that reduce food intake, alter metabolism, or increase 
energy levels, such as adrenergic thermogenic drugs, will be in demand as the proportion 
of overweight and obese people increases. 
2.3.3 Diabetes 
The number of people with diabetes in China is escalating, with the potential of 
reaching unknown dimensions.  According to Festel et al. (2005), Diabetes is a multi-
factorial disease in which the genes not only interact with each other, but also with 
environmental factors.  Genetically predisposed individuals will not necessarily develop 
Type 2 diabetes unless they are also exposed to environmental factors. With the 
increasing demographic shifts and affluence, Festel et al. (2005) estimates that the 
number of people with diabetes in China may exceed 150 million by 2025. There are 
three principle explanations for the rising prevalence of diabetes in China. Cheng (2003) 
points out that the prevalence of diabetes is much higher than previously reported 
because three out of four diabetic patients in China are undiagnosed. The lack of 
population-based screening programs is one the reasons for the large number of people 
who are unaware of their condition. Additionally, Cheng (2003) explains that a lower 
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baseline body mass index among the Chinese to begin with means that it takes less 
increments to reach an obese level and smaller increments to increase the risk of type 2 
diabetes in the Chinese population. There is a close relationship between those who suffer 
from diabetes and obesity.  Another relationship also exists with hypertension, which is 
one the most common co-morbidities linked to diabetes (Festel et.al, 2005). The third 
explanation for the growing prevalence of diabetes among the people in China is a result 
of the positive association between cigarette smoking and the risk of diabetes in Chinese 
men.  Smoking is growing in usage in China, and it has an odds ratio of 1.7 on the risk of 
diabetes (Cheng, 2003).  
2.3.4 Tobacco Usage 
China is the world largest grower and consumer of tobacco; for every three 
smokers in the world, one is a Chinese man (Yang et al., 2008). The rate of tobacco 
production has increased from 80 billion individual cigarettes in 1949 to 1723 billion in 
2002, while consumption of cigarettes increased to 2022 billion in 2006 (Yang et al., 
2008). China only exports 0.8% of the cigarettes produced in China.  They consumed the 
remaining 99.2%. On average, a Chinese man consumed about 15 cigarettes per day in 
2002. Passive exposure to tobacco smoke affects 52.5% of the Chinese population, and 
this number did not change between 1996 and 2002. Table 2:2 shows the age-
standardized prevalence rates and estimated populations at risk from smoking compared 
to those suffering from hypertension and obesity.  According to Yang et al. (2008), 82% 
of passive smokers reported exposure at home; 35% at their workplace; and 67% in 
public places. A study in rural China found that money spent on tobacco negatively 
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affected the amount of money spent on health, education, farming equipment, and seeds 
(and thus future productivity).  Tobacco expenditures also affected savings and insurance 
(Wang et al., 2006). Every 100 Yuan spent on tobacco resulted in a decline in spending 
on education by 30 Yuan, on health care by 15 Yuan, on farming by 14 Yuan, and on 
food by 10 Yuan (Suhrcke et al., 2006).   
Table 2:2 Age-standardized prevalence rates and estimated populations at risk 
 Age-standardized 
prevalence rate 
Average increase, 
compared with 
most recent survey 
Estimated 
population at 
risk 
People with 
hypertension 
17.7% 2.67% 177000000 
Overweight people 17.6% 3.23% 218000000 
Obese people 5.6% 5.43% 68000000 
Current smokers 28.2% -2.91% 303000000 
Male current 
smokers 
53.2% -3.01% 290000000 
Female current 
smokers 
2.2% -8.26% 13000000 
Passive smokers 52.2% -0.49% 530000000 
(Source: Yang et al., 2008) 
There are numerous risk factors associated with smoking. Of the 4000 known 
chemicals in cigarettes, 50 or more are carcinogenic. With passive and full time smokers 
combined, there are well over 800 million people at risk in China. Pharmaceutical 
intervention with nicotine-replacing drugs or non-nicotine drugs, such as Chantix, will be 
needed to help reduce the urge for smoking as a preventative measure. Cancer drugs 
needed for chemotherapy or radiation therapy will be needed to help those who will or 
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already suffer from diseases such as throat cancer, lung cancer, or chronic bronchitis, to 
name a few.  
2.4 Rural and urban areas 
The death rates in China vary between the rural and urban areas and between the 
populations in the eastern, middle, and western regions of the rural areas (Yang et al., 
2008). The rural areas have seen a higher mortality rate from communicable diseases, 
maternal and prenatal conditions, chronic obstructive pulmonary diseases, and injuries. 
However, the urban areas have had higher death rates from cardiovascular diseases and 
cerebrovascular disease.  Table 2:3 outlines various communicable and non-
communicable disease-related deaths per 100,000 people through the various regions in 
rural China and the urban regions. 
Table 2:3 Age-standardized rates of death from different causes in 2004 and 2005 
 Urban Rural    
  Total Eastern 
regions 
Middle 
regions 
Western 
regions 
Communicable diseases 16 27 18 23 42 
Maternal and perinatal conditions 5 7 6 7 10 
Cancer 127 125 131 133 107 
Cerebro-cardiovascular causes 193 210 195 254 180 
Chronic obstructive pulmonary 
disease 
52 81 65 80 103 
Other non-communicable diseases 49 48 43 42 61 
Injury 44 66 63 65 72 
Unknown 13 8 10 7 6 
Total 499 572 531 610 581 
Data are deaths per 100,000 
population. 
     
(Source: Yang et al., 2008) 
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In both the urban and rural areas, the 2006 mortality survey showed that lung 
cancer, breast cancer, and leukaemia were higher in urban areas, while oesophageal 
cancer and cervical cancer were higher in rural areas (Yang et al., 2008). These variations 
in types of disease based on regions and rural and urban locations give healthcare 
providers and pharmaceutical companies a better understanding of not only the increasing 
incident of chronic diseases, but also a better insight on where to sell specific disease-
related drugs and where to conduct clinical trials.  
2.5 Summary 
In summary, the ageing population of China and the shift towards more social 
reform has affected the rate of increase in chronic diseases in China. There has been a 
steady increase in the standard of living and the rate of urbanization. The dietary 
structure, physical activity levels, obesity, and diet-related non-communicable diseases 
are changing at a rapid pace throughout the emerging markets. China is the largest 
populated nation in the world reflecting many of these changes.  
 
It is important to consider that these economic shifts have not been consistent 
throughout all regions in China. There are large subpopulations that have been bypassed 
by progress. The type of foods being consumed has shifted in both the urban and rural 
areas. The diets of all income groups have shifted, with the greatest shifts being seen in 
those in the urban locations and those with high income. Some of the conditions in need 
of pharmaceutical drug intervention include hypertension, obesity, diabetes, and tobacco 
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addiction. The rural areas of China have seen a higher mortality rate from communicable 
diseases, maternal and prenatal conditions, chronic obstructive pulmonary diseases and 
injuries. However, the urban areas have had higher death rates from cardiovascular 
diseases and cerebrovascular diseases.  
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3: Overview of China’s healthcare system 
The severe acute respiratory syndrome (SAR) crisis in China revealed some of the 
failures of the Chinese health care system, as well it showed some fundamental structural 
deficiencies (Liu, 2004). The decentralized and fragmented healthcare system of China is 
not well suited for making a rapid and coordinated response to public health emergencies 
(Liu, 2004). According to Liu (2004), the commercial orientation of the health sector on 
the supply-side and the lack of health insurance coverage on the demand side have 
exacerbated the under provision of public services problems, such as health surveillance 
and preventive care. A closer analysis of China’s healthcare system is needed to 
understand its ability to handle the rising number of people with chronic diseases within 
the country.  
3.1 Weakened government role, communication, and control  
The state council is the premier governmental body that is responsible for 
implementing the national policies and having jurisdiction over the 22 provinces, 3 
municipalities, and 5 autonomous regions of China (Hiller & Shen, 1996). Below the 
provincial governments are the county governments. With the increase in urbanization, 
the number of counties within the country is estimated to be around 2000 (Hiller & Shen, 
1996). The county government has control over the independent township governments. 
The lowest on the hierarchy in terms of governmental power are the individual villages. 
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The public health system utilized throughout these provinces is comprised of Epidemic 
Prevention Stations (EPSs). These EPSs are situated on different administrative levels of 
the government. These EPSs are responsible for conducting health surveillance, 
collecting information from hospitals, and reporting to the next level up of EPS 
administration. However, as noted by Liu (2004), communication between these various 
levels of EPS is weak.  This results in missing data in the Ministry of Health’s annual 
statistical reports.  Consequently, the Ministry of Heath’s role in creating and sustaining 
public health programs has diminished.  
China’s total health spending as a percentage of the country GDP has increased 
from 4.11% in 1991 to 4.82% in 2000.  However, all government spending on health as a 
share of total health spending has decreased from 22% in 1991 to 14% in 2000 (Liu, 
2004).  The individual citizen of the country has increased their out of pocket spending as 
a share of total health spending from 38% to 60% from 1991 to 2000. The weakened 
government role on health spending has occurred at a time when China is facing 
increased complications in national health. Increased industrial pollution, increased 
chronic diseases, and urbanization because of easing of restrictions for mobility are 
increasing the strain on the health system. The lack of investment by the Chinese 
government has undermined health surveillance services and prevention services (Hu et 
al., 2003).  
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3.2 Fragmentation of healthcare system 
The clinics and hospitals in China are owned and operated by a diverse number of 
groups, such as state owned enterprises, military establishments, private investors, and 
local cooperatives (Liu, 2004). There are inadequate regulations regarding health 
responsibilities by these organizations. Additionally, there are few mechanisms in place 
for enforcing the regulations.  According to Liu (2004), ever since China’s 
decentralization of the fiscal system in the late 1980’s, competition for investment and a 
desire for marketplace dominance among provinces and cities has been intensified which 
possibly makes it difficult for local governments to share information and work in 
partnership in areas such as public health. There are bureaucratic challenges associated 
with detecting and reporting chronic diseases. Some authorities find that releasing 
information of such diseases will cause civil unrest within the province or affect the 
amount of foreign investment and tourism.  
 
The decentralized fiscal system in China is leading to increased variations in 
investment in the healthcare system by the individual provinces, cities, towns, and other 
entities. Variations in the level of performance have become a growing concern as well. 
While some regions are equipped to detect and control epidemics in their area, for 
example Guangzhou and Beijing, other areas are unprepared for major public health 
challenges (Liu, 2004). The townships are worst off, as they often do not have EPSs in 
place.  These townships also lack supervision and coordination in healthcare providers 
that are present in these areas (Liu, 2004).  
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3.3 Market forces 
The government of China’s role in the healthcare system has been reducing; 
instead, the role has been shifting to the market forces (Jamison, 1984). Market forces 
have enabled a positive progress in the health sector, most noticeably is the increase in 
the supply of modern health facilities and the increase in the variety of medicine available 
for treating diseases and illnesses (Liu, 2004). China’s total supply of heath professionals 
and hospitals beds have increased significantly.  By 2001, there were 5.5 million health 
professionals and 3.2 million hospital beds. However, these improved health services 
benefit people who are able to afford it. The increasing privatization of health care 
financing, says Liu (2004), creates inequalities in health care and in health status. 
Moreover, healthcare providers have become less interested in public health work than 
medical treatment because there is little or no remuneration for preventative services, and 
there is increasing pressure for providers to generate revenues.  
3.4 Economic and healthcare costs to China 
China’s population faces substantial direct and indirect costs associated with 
chronic diseases. Direct costs stem from admission to hospitals, medical costs, costs of 
prevention, and care related travel, nursing, and family support (Yang et al., 2008). Low 
productivity, sick leave, loss of workforce due to early retirement, and premature deaths 
are a few examples of the indirect economic costs to the country. Costs to families who 
may or may not have some form of medical insurance for treating conditions such as 
hypertension, diabetes, coronary heart diseases, stroke and cancer averaged 4000-10000 
Renminbi (7 Renminbi = US $1) (Yang et al., 2008).  The average yearly urban income is 
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9422 Renminbi per year, and 2936 Renminbi for a rural family (Yang et al., 2008). These 
in-patient treatments for chronic diseases can cost up to half the annual salary for urban 
residents and three times the annual income of rural residents. Chronic diseases not only 
have health burdens but economic ones as well, especially upon the newly reformed 
healthcare system of China. Chronic diseases drive up costs because of the need to use 
advanced technologies for treatment. There needs to be a tighter integration of primary, 
secondary, and tertiary care services in order to channel the treatment for chronic disease 
to the most cost efficient levels of the healthcare system (Yang et al., 2008).  
For cardiovascular diseases alone, says Wang (2005), Chinese people aged 35-64 
years lost 6.7 million years of productive life during the year 2000. This cost China 
approximately US $30 billion, of which only a quarter of this amount was direct health 
care costs. Wang (2005) estimates that, if the current trend for this age group continues, 
the total years of productive life lost will increase to 10.5 million by 2030. China is 
estimated to lose $18 billion in national income ever year after 2005 as a result of heart 
disease, stroke, and diabetes on labour supplies and savings (Wang, 2005).   The 
cumulative loss over the period of 2005-2015 would be about $556 billion.  
3.4.1 Health insurance  
The percentage of urban and rural people with health insurance dropped from 
12% to 9% in 1998. Due to the high cost of medical care, pharmaceuticals, and the lack 
of medical insurance, the total health care utilization rate in China has fallen (Liu, 2004). 
In poverty-stricken regions, the admission rate into hospitals for those without insurance 
is 35 per 1000, while those with insurance are 251 per 1000. The patient initiates the 
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majority of the discharges out of the hospitals in these regions mainly because they can 
no longer afford the medical treatment (Hu et al., 2003).  Many of those without 
insurance do not report illnesses or seek professional help, which leads to the eventual 
deterioration of their health. From a public health perspective, those not reporting 
illnesses may have infectious diseases that could spread.  If officials do not identify and 
isolate these diseases on time, it can lead to potential epidemic outbreaks (Liu, 2004). 
China has implemented government-subsidized insurance for those in rural areas.  
However, this insurance is only intended to cover medical costs that become 
‘catastrophically’ expensive for an individual.  
3.5 Commercialization of healthcare 
Towards the mid 1980s, the Chinese government tightened the budget for public 
hospitals and health care organizations (Yin, 2002).  The public sector hospitals were 
expected to generate funds to meet the costs not covered by the government budget 
allocation. Government policies have kept the price of hospital services relatively low.  
However, hospitals and health care providers are allowed to add a 15 – 20% mark up on 
the wholesale price of drugs (Liu, 2004).  This creates an incentive for the hospitals and 
healthcare providers to prescribe and sell more drugs.  Pharmaceuticals MNCs need to be 
aware of these drug pricing policies by hospital when selling their products to them.  If 
the MNCs sell the product for too high a price, the hospitals will demand even more from 
the patients, possibly making the drug unaffordable for many.   
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The EPS has also had to find ways to deal with budget cuts for providing public 
health services.  In 1985, the government funded 80% of the EPS’s total income; by 
1997, this number had dropped to less than 40%.  The EPS have had to find ways to 
generate funds, one way was to add service fees to annual physical examinations for 
urban workers and middle school students (Liu, 2004).  
 
An important aspect for pharmaceutical companies to consider is the convincing 
of health practitioners to prescribe their drugs to patients.  However, with the 
commercialization of the health sector, identifying practitioners with qualifications to 
understand the effects of their drugs has become difficult. Before the economic system 
was reformed, the rural health system was an integrate system with formal bottom up 
referral processes for patients. There were regular technical supervisions provided to the 
lower health facilities by the upper facilities (Liu, 2004). However, the reform has lead to 
the collapse of the Cooperative Medical System, resulting in the fragmentation of the 
rural health care delivery system (Liu, 2004).  This fragmentation in the system has 
created different health facilities competing for revenues from the patients.  The village 
medical supervisors who once were supervised by upper level facilities now have little 
supervision or professional training.   
 
The village health practitioners are the first point of contact for many rural 
patients in this medical system (Liu, 2004).  With practitioners not receiving further 
training or supervision, these villagers may suffer from unsafe medical practices.  Liu 
(2004) discovered a joint study between the United Nations Children’s Fund and the 
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Ministry of Health that found that the practice of unsafe prescribing and giving of 
unnecessary prescriptions was widespread among China’s village health practitioners.  A 
study in 1998 found these village practitioners unnecessarily prescribed corticosteroids in 
20-36% of the prescription given out. While 46-64% of children received intramuscular 
injections for the common cold (Liu, 2004).  Most of these practitioners did not keep 
medical records of the drugs prescribed to their patients thereby raising technical and 
ethical concerns.  
3.6 Summary  
The decentralized and fragmented healthcare system of China is not well suited 
for making a rapid and coordinated response to public health emergencies.  China’s total 
health spending as a percentage of the country’s GDP has increased; however, all 
government spending on health as a share of total health spending has decreased. The 
weakened government role on health spending has occurred at a time when China is 
facing increased complications in national health. Rising industrial pollution, chronic 
diseases, and urbanization have increased the strain on the health care system. The lack of 
investment by the Chinese government has undermined health surveillance services and 
prevention services.  
 
In-patient treatments for chronic diseases can cost up to half the annual salary for 
urban residents and three times the annual income of rural residents. Chronic diseases not 
only have health burdens but economic ones as well, especially upon the newly reformed 
healthcare system of China. Variations in the level of healthcare performance have 
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become a growing concern. While some regions are equipped to detect and control 
epidemics in their area, other areas are unprepared for major public health challenges.   
 
The percentage of urban and rural people with health insurance has dropped. Due 
to the high cost of medical care, pharmaceuticals, and the lack of medical insurance, the 
total health care utilization rate in China has fallen.  Pharmaceutical companies 
convincing health practitioners to prescribe their drugs to patients need to be aware that 
the commercialization of the health sector has made it difficult in identifying practitioners 
with the necessary qualifications to understand the effects of their drugs. 
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4: Business opportunities in China’s pharmaceutical market 
Pharmaceutical corporations will find many opportunities in China’s changing 
markets to establish a profitable presence.  This chapter explores the entry barriers for 
pharmaceutical multi-national corporations, such as the changing market, clinical 
research opportunities, intellectual property rights, bribery and corruption, tax incentives, 
and drug pricing.  Other entry barriers include complex distribution channels, strategic 
regions in China, and financial reporting.  This chapter also covers the bargaining power 
of buyers, the threat of substitutes, the bargaining power of suppliers, and the competitive 
environment.   
4.1 Background 
China’s pharmaceutical market has achieved record growth and is becoming 
increasingly healthy. As of 2007, China represents a $15 billion market for 
pharmaceutical products (Zhou, 2007). It is expected that China will become the world’s 
fifth largest pharmaceutical market, rising to $24 billion (PWC, 2004). With such 
expectations, there has been an increased interest in foreign investment into China. 
Currently, there are about 1700 Sino-foreign joint ventures in the pharmaceutical sector 
(PWC, 2004), including many of the largest pharmaceutical companies such as Novartis, 
Pfizer, and Roche.  These multinational companies (MNCs) want to expand Chinese 
operations to gain greater market share, but there are obstacles to consider.  
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  The amount of heterogeneity in customers, suppliers, competitors, regions, and 
government entities adds to the business complexity. Nearly 60% of the economy is 
represented by China’s east coast provinces; however, only 30% of the population live 
there (Festel et al., 2005). Some positive factors for investment into China include vast 
consumer demand for pharmaceutical products, lower labour costs, and cost-effective 
opportunities for R&D and clinical trials.  
The following chapter will use Michael Porter’s (1979) five forces framework.  It 
will go into detail regarding entry barriers, the bargaining power of customers, the 
bargaining power of suppliers, the threat of substitute products, and the rivalry in the 
pharmaceutical industry environment.  
4.2 Entry barriers for pharmaceutical MNCs 
China’s entrance into the World Trade Organization (WTO) has helped to reduce 
the threat of entry into this market; however, the threat of entry remains high. The WTO 
has enabled implementation of medical insurance, increased pharmaceutical regulations, 
and created a stronger patent system. China’s pharmaceutical market was already quite 
competitive before the country gained WTO membership (Festel et al., 2005). As of 
2004, foreign drug makers will be able to import and distribute products in any part of 
China, with an average import tariff of 4.2 %, with an additional 17 percent value-added 
tax (APBN, 2003). However, only approximately 10% of China’s national population is 
covered by the country’s health insurance network. Urban insurance reform is a 
significant issue facing foreign MNCs and the Chinese government (PWC, 2006).  
  
38 
4.2.1 A changing market 
The market is quite fragmented with about 6000 small-scale domestic producers 
struggling to make profits (PWC, 2004). These producers perform relatively little R&D 
as approximately 97% of the drugs they produce are copies of foreign products (PWC, 
2004). The State Food and Drug Administration (SFDA) are in charge of monitoring 
pharmaceuticals and enforcing the Good Manufacturing Practice (GMP).  However, only 
two thirds of the manufacturing base in 2004 was GMP certified. Some companies are 
unable to meet the capital investment required to get GMP certification and are thus faced 
with either consolidating or being acquired by foreign investors (PWC, 2004). The 
following pie charts (Figure 4:1 & 4:2) show the projected change in the pharmaceutical 
market profile from 2000 to 2010. There is a shift towards increased usage of over-the-
counter, patented, and branded generics, with a 25% reduction in the usage of generic 
products.  
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Figure 4:1 Chinese pharmaceuticals market profile, 2000 
 
(Source: PWC, 2004) 
 
Figure 4:2 Chinese pharmaceuticals market profile, 2010 forecast 
 
(Source: PWC, 2004) 
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4.2.2 Clinical research opportunities  
Entry barriers have been reduced with China offering a competitive advantage for 
foreign MNCs investing in Chinese pharmaceutical research. Between 2000 and 2007, 
China’s research and development expenditure increased at an average rate of 26.5% 
annually (PWC, 2009). During this same period, the R&D/GDP ratio for China increased 
to 1.49% in 2007, compared to United States R&D/GDP ratio of 2.66% in 2007. The cost 
for performing clinical trials in China is significantly lower than in North America. The 
cost to employ a Chinese college graduate is US $3,980 per year.  This provides 
opportunities for pharmaceutical MNCs to hire locally and conduct R&D activities at 
significant cost advantages (PWC, 2009). There are over 200,000 highly skilled research 
scientists willing to participate in clinical trials for approximately one-fifth of American 
salaries (PWC, 2004).  As of 2007, China has nearly 20,000 hospitals, over 2 million 
physicians, and 1.42 million nurses, making the country an attractive location for clinical 
trials. China also has a liberal research environment and a large number of untreated 
patients. Clinical trials conducted in China would provide access to data that covers a 
different ethnic population and genetic variations.  The acquisition of such data would 
play a large part in determining both susceptibility to disease and the safety and efficacy 
of the drugs needed to treat the conditions (PWC, 2004). Clinical research centres in 
China have the support of the Chinese government through strong incentive programs to 
support the industry. These incentives come by way of tax reliefs, direct funding 
opportunities, and development of numerous technology parks (PWC, 2009).  
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The most important government agencies driving pharmaceutical and 
biopharmaceutical R&D include the Ministry of Science and Technology (MOST), the 
State Food and Drug Administration (SFDA), the National Development and Reform 
Commission (NDRC), and the Ministry of Commerce (MOFCOM).  MOST is 
responsible for overall management of technology developments. This includes studying 
and formulating policies, laws and regulations; evaluating, issuing and organizing 
implementation of projects; formulating annual programs; determining the direction of 
investment; monitoring and checking the implementation of plans; and organizing 
international cooperation (Webber, 2003).  The SFDA is responsible for numerous 
aspects of drug regulation and registration. The NDRC is responsible for setting prices of 
medicines. According to Webber (2003), the NDRC can achieve a principle impact on 
R&D through supporting pricing of products that reflect the high levels of investment 
needed for R&D.  Similarly, the Ministry of Health (MOH), which is responsible for 
hospital management generally, can affect the industry through its policies on hospital 
bidding and procurement. MOFCOM is the body that is responsible for investment and 
business policies for domestic and foreign enterprises (Webber, 2003). This ministry sets 
the policies for foreign investment.  
4.2.3 Intellectual property rights 
MNCs face certain barriers to entry into the pharmaceutical R&D market in 
China.  The protection of intellectual property (IP) rights in China serves as a deterrent, 
with the People’s Republic of China (PRC) showing political and legal reluctance in 
upholding patent rights of foreign investors. Intellectual theft occurs on various levels 
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including small scale reversing and copying, counterfeiting, systematic reverse R&D, and 
reverse engineering (PWC, 2004). Counterfeit drugs account for 192,000 Chinese deaths 
every year and a cost of $2.6 billion in losses as a result of piracy.  Regulatory difficulties 
are another deterrent. Getting drugs registered and obtaining production and sales permits 
involves various central, provincial, and local authorities, taking at times several years for 
approval (PWC, 2004). Large-scale improvements in IP enforcement cannot be expected 
until Chinese-made pharmaceutical brands begin to require the protection (PWC, 2006). 
However, in recent years Chinese domestic pharmaceutical producers have successfully 
sued foreign and domestic companies in Chinese court for intellectual proprietary 
violations. Pharmaceutical corporations are looking to other sectors and have reason to be 
pleased, as the Chinese government has begun cracking down on all types of intellectual 
property infringement, such as unlicensed music downloads. The legal framework 
enabling MNCs to protect their property and successfully sue violators is strengthening 
across all IP industries in China (PWC, 2009). A key success factor for multinational 
pharmaceutical corporations entering China would be to find ways to ensure that they 
have protected themselves as best as possible from intellectual property infringements.  
4.2.4 Bribery and Corruption  
The pharmaceutical industry in China is prone to bribery and corruption due to 
the many levels of distribution, sales, representatives, physicians, and government 
officials involved in the market. As recently as mid 2008, the US Department of Justice 
handed out a $2 million dollar fine against AGA Medical Corporation due to allegations 
of illegal payments to government officials in China, and payments to the China State 
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Intellectual Property Office (PWC, 2009). In 2007, China investigated over 1000 bribery 
cases regarding the purchasing and distribution of drugs. The government has outlined 
that it will take aggressive steps to reduce bribery and corruption in the medical and 
pharmaceutical sectors. It plans to do this through the expansion of its online 
procurement system for hospitals (PWC, 2009).  This system is used in 20 provinces and 
handles 85% of the purchasing of hospital drugs.  It allows for monitoring, controlling 
costs, and improving transparency.  However, drug companies still give incentives to 
those doctors that write more prescriptions for their drugs.  
 
Doctors distribute most pharmaceuticals through hospitals in China, which 
depend on drug sales for nearly 80% of hospital revenue. This has lead to some barriers 
for foreign pharmaceutical corporations as the hospitals tend to favour locally produced 
generic drugs, a market in which corruption exists (PWC, 2004); multinationals may be 
asked to provide incentives or bribes for hospital officials and doctors (PWC, 2006). In 
an attempt to combat this problem, the government has put regulations in place to 
encourage local development of retail pharmacies and has permitted foreign investment 
(Zhou, 2007).  A key success factor would be for foreign companies to invest in and 
improve underdeveloped retail options for Chinese consumers, which not only can 
increase brand awareness but also increase drug usage. The government has gone further 
to segregate the entities responsible for the writing and filling of prescriptions, reducing 
the chances that doctors and hospitals will collude to write excessive prescriptions to be 
filled by the hospital’s dispensaries.  The growth of retail pharmacies outside the 
hospitals can help to reduce this corruption in the hospital system (PWC, 2009).  
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Foreign multinational corporations considering investment or acquisitions in 
China should be aware of the risk they take in acquiring Chinese companies that may 
carry out illegal practices or regulation violations.  New owners can be held accountable 
for these allegations after purchasing or acquiring the company (PWC, 2009). Foreign 
companies looking to expand in China via mergers or acquisitions should put in place 
procedures and policies in their due diligence for detecting bribery and corruption (PWC, 
2009).  
4.2.5 Tax incentives 
As of January 1, 2007, the Chinese government introduced the new Corporate 
Income Tax (CIT) law along with other regulations to act as tax incentives and schemes 
to encourage R&D growth and investment by foreign MNCs in China. Some of the key 
income tax incentives that are available to pharmaceutical companies to improve their 
overall tax efficiency in regards to Chinese operation include the High/New Technology 
Enterprise (HNTE) Incentive, the CIT super deduction, and the income tax exemption for 
the transfer of technology (PWC, 2009). The HNTE incentive is for those corporations 
that are qualified as HNTEs upon assessment by relevant authorities. In order to qualify, 
the company should have ownership of core proprietary IP rights, products/services 
falling under the scope of “encouraged” domains and R&D expenditures, income from 
relevant activities, and a minimum number of R&D/technical personnel meeting 
requirements (PWC, 2009). Companies may need to consider re-planning, restructuring, 
and managing their IP strategies differently in order to obtain HNTE status. Upon 
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approval, these HNTE corporations are entitled to a reduced corporate income tax of 15% 
as opposed to the standard CIT rate of 25%.   
 
The Chinese government created the CIT super deduction to encourage 
pharmaceutical R&D activities. The super deduction gives companies an extra 50% 
expense deduction for eligible R&D costs endured.  These R&D costs include expense 
from development of new technologies and products, salary expenses for R&D 
personnel, and the depreciation of instruments and equipment used for R&D purposes 
(PWC, 2009).  
 
The income tax exemption for the transfer of technology, which is defined as the 
portion of the income derived from the transfer of technology during a tax year- not 
exceeding RMB $5 million- can be exempt from CIT. The portion that exceeds RMB $5 
million is eligible for a 50% reduction in corporate income tax (PWC, 2009).  
4.2.6 Drug Pricing 
The NDRC has put in place policies to control the pricing of drugs, as this is in 
the main interest of the Chinese government who is the primary payer of healthcare costs. 
Nearly 2,400 types of drugs have a maximum retail price that is set. However, this 
accounts for only 20% of the available drug products and 60% of overall drug sales 
revenue in China (PWC, 2009). Drug pricing is still not under control because of the drug 
distribution system and hospital dependence on drug pricing for revenues. The drug 
distribution system in China is highly complex with many intermediaries that operate 
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between the drug manufacturers and the hospitals. This results in the cost of the drug 
inflating several times over as it moves along the chain. With government subsidies 
covering only 6% of hospital expenses, hospitals are dependent upon the revenue from 
drug sales. The government gives hospitals the right to mark up prices on drugs by 15% 
(PWC, 2009).  Thus, the hospitals buy the most expensive drugs from those 
intermediaries that have inflated the price several times over, making the intermediaries 
and the hospitals wealthier while putting the consumer at a disadvantage.  
 
Since 1996, the Chinese government has imposed 24 price cuts on over 2,000 
pharmaceutical compounds and 300 traditional Chinese medicines. On average, each 
price cut across all categories was approximately 20%.  From 2003 to 2006, the average 
profit percentage in the pharmaceutical industry decreased from 9.7% to 6.3% (Ziyan, 
2007). These drug-pricing cuts have failed to have a significant impact because hospitals 
and retailers simply switch brands when prices drop too low. Drug manufacturers change 
packaging, or make subtle changes to the ingredients in drugs so that they can register 
these altered drugs as new products and avoid the prices restrictions (PWC, 2009). In 
2007, Chinese pharmaceutical companies filed a complaint stating that the drug pricing 
cuts were not fair to the manufacturers as the hospitals are the culprits in setting high 
prices and raising drug costs. The NDRC is expected to introduce price-ceiling 
regulations for all prescription drugs at different stages in the supply chain, including ex-
factory, wholesale, and retail, in an attempt to keep healthcare costs down and prevent 
irregularities and price manipulations through the distribution system (PWC, p.15, 2009). 
It is important for foreign and domestic pharmaceutical companies to incorporate drug 
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pricing into their corporate strategies. More importantly, a key success factor for foreign 
pharmaceutical corporations would be to find ways to manage the pricing controls and 
pressures within the Chinese pharmaceutical market.  
4.2.7 Complex distribution channels 
Foreign pharmaceutical corporations also need to consider the obstacles involved 
in working with limited distribution systems. The state-owned traditional distribution 
system has hindered the creation of a national distribution system because it favours 
provincial and local networks (PWC, 2006). With the introduction of the “Good Supply 
Practice” (GSP) certification, the number of wholesalers within China has dropped from 
16,000 down to 7,500 (Zhou, 2007).  The state has also created pharmaceutical logistics 
and electronic trade systems in many Chinese cities. However, the industry continues to 
be 80% dominated by small distributing companies. Only 10 wholesalers throughout 
China have exceeded 1 billion RMB in revenue and even fewer have exceeded 5 billion 
RMB (Zhou, 2007). The market share for three of the largest distributors was only 17% 
in 2005 (Zhou, 2007), indicating an unhealthy competitive environment. These 
distributors will likely attempt to become product agents and try to earn profits through 
commission-based sales and discounts from manufacturers (Zhou, 2007).  A thorough 
understanding by foreign multination corporations of the complex distribution channels 
can act as a key success factor to doing business in China. 
 
The distribution system in China is three tiered. Most pharmaceutical MNCs 
distribute their manufactured goods through national and provincial wholesalers, who 
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then sell the drugs to hospitals, clinics, and pharmacies. From there the products are sold 
to the consumers (PWC, 2009). Approximately 80% of the Western style drugs are 
distributed through the hospitals and clinics while the remaining 20% is distributed 
through the retail pharmacies. Leading distributors in China include CNPG, Shanghai 
Pharmaceutical Group, and Guangzhou Pharmaceutical Group, which are building 
regional networks and selling directly to hospitals and the retail sector (Brueckner, 2005). 
The retail sector is comprised of three different outlets for selling medical drugs and 
healthcare products.  The first of these are chain drugstores; the second are the discount 
pharmacies (there are estimated to be over 1,000 of these discount pharmacies selling low 
price generic drugs); and the third are pharmacies that are designated for reimbursements 
(Brueckner, 2005).  
Figure 4:3 China’s distribution channels - overview 
 
(Source: PWC, 2009) 
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Drug manufacturers are demanding increased transparency in the distribution 
system to better track where their product is being sold (PWC 2006). In response, the 
Chinese government has allowed foreign third party logistic providers to enter and create 
joint ventures with local distributors (PWC, 2006). The government has also provided 
financing to encourage domestic distributors to build new logistical systems to help 
reduce the barriers to entry for foreign MNCs. The current operation modes of most 
distributors also need to be more in line with the requirements of modern distribution, 
which includes increased scale, automation, and tracking capabilities (Zhou, 2007). 
Increasing logistical management knowledge and improving market development and 
service capabilities is imperative (Zhou, 2007). Improving these distribution channels 
would directly affect drug pricing, which is hugely inflated by these distribution 
intermediaries (PWC, 2006). The lack of scale by distributors forces manufacturers to use 
multiple distribution firms to get their products to retailers. Without tracking systems in 
place by distributors, pharmaceutical manufacturers do not have full guarantees on the 
whereabouts of all their products. This makes it very difficult to initiate product recalls, 
and creates an enormous vulnerability for counterfeit products entering into distribution 
channels. Furthermore, having multiple distributors through the chain can negatively 
affect product quality, especially for cold products.  
 
In 2004, Beijing Pharmaceutical Group Co. Ltd. built the first modern 
pharmaceutical logistics centre, using foreign bought advanced logistics equipment and 
technologies (PWC, 2009). However, foreign firms dominate in certain areas.  For 
instance, the global giant, World Courier Inc., launched a cold chain logistics network in 
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China, and provided pharmaceuticals to 36 major cities with access to temperature-
controlled shipments (PWC, 2009).  
4.2.8 Strategic regions in China 
With over 9.5 billion square kilometres, China does not have uniform population 
dispersal, wealth, and economic power. There is a decreasing GDP per capita per 
province from the east to the west of China, and foreign MNCs are focusing their 
business on the wealthier coastal provinces (Zedtwitz, 2005). The eastern provinces have 
more people that are able to afford expensive and modern drugs because they have higher 
incomes.  In addition to this, the eastern provinces have better education and higher 
disease awareness. With different market characteristics, foreign MNCs investing in 
China need to adjust their market development strategies to fit the demands and 
opportunities of targeted Chinese provinces (Zedtwitz, 2005). Having a clear 
understanding of the market and regulatory landscape can be a key success factor for 
foreign multinationals investing in the country. Surveys have found that GDP growth per 
capita is nearly twice has high in certain eastern provinces than those in the west. 
Strategically important eastern provinces include major cities such as Beijing, Shanghai, 
Tianjin, Guangdong, and the comparatively wealthy provinces of Shandong, Zhejiang, 
Jiangsu, Guangzhou, and Fujian (Zedtwitz, 2005).   The city of Chongqing is of strategic 
importance to drug manufacturers because it is one of the largest cities with a populous of 
over 30 million.  This makes Chongqing ideal for distributions and clinical trials. These 
provinces and cities listed above represent approximately 75% of the prescription 
business in China.   
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Pharmaceutical companies also need to consider the different ways of conducting 
business in these varying regions. The strategic wealthier provinces and cities need to be 
managed at a higher professional level, including more transparency in the 
implementation of drugs, hospital bidding processes, and availability of data for patients 
and diseases (Zedtwitz, 2005). However, the central and western regions require more 
relationship-driven business, paying close attention to price sensitivity. Pharmaceuticals 
tend to introduce more innovative, newer drugs in the eastern regions and to distribute 
more mature and less expensive drugs in the developing central and western markets of 
China (Zedtwitz, 2005).  
4.2.9 Financial reporting  
Pharmaceutical MNCs establishing operations or making mergers and acquisition 
need to be aware of China’s financial reporting methods. Companies investing in Chinese 
pharmaceutical companies will find that many of these firms have not been using 
comprehensive accounting rules such as the Generally Accepted Accounting Principles 
(GAAP) used in the U.S., or the International Financial Reporting Standards (IFRS) 
(PWC, 2009). Public Chinese companies were required to adopt Chinese Accounting 
Standards (CAS) as of January 1, 2007; however, this was not required of private 
companies. As a result, many of the private companies in China prepare their accounting 
records on a cash basis resulting in many unrecorded or undisclosed transactions. PWC 
(2009) recommends that foreign MNCs investing in companies in China’s 
pharmaceutical market put in place ongoing monitoring of performance and accounting 
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methods to ensure proper operating and financial decisions. Investors should also 
consider their exit strategies through either selling the company or making initial public 
offerings. Investors need to ensure that the company’s financial statements and 
accounting methods are in alignment with those of the exchange and regulatory bodies 
(PWC, 2009).  
4.3 Bargaining power of buyers  
 China has effectively two markets, urban and rural. The bargaining power of 
buyers from both these markets for drugs remains relatively low (PWC, 2004). Although 
personal disposable income and awareness for medicine and drugs is increasing 
nationally, it has not given the consumers the ability to control prices. Demographic 
influence on the use of drugs has been the result of mass movement of people from the 
rural countrysides into the major cities of China (Bao, 2000). The urban population has 
been steadily increasing at about 4.5% per year. According to Qi Bao (2000), 
urbanization generates lifestyles more conducive to pharmaceutical usage. It also 
generates awareness and enables greater access to drugs through retail pharmacies (Bao, 
2000). Foreign companies attempting to enter China should consider that the rural 
population accounts for approximately 70% of the total population; however, they only 
consume 20% of the pharmaceutical products sold (Bao, 2000). Though national 
disposable income may be increasing, rural disposable incomes remain low, along with 
the consumption of modern drugs (PWC, 2004).  
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Even though these income disparities exist, the overall demand for drugs is 
growing rapidly, particularly for those drugs that are used in certain therapeutic 
categories (PWC, 2004). As China becomes a more developed nation, its epidemiological 
profile is changing; people are eating more and exercising less. This has led to an 
increase in the incidence of cardiovascular disease, which is now the most frequent cause 
of death in China (PWC, 2004). The over 60 population within China also serves as a 
tremendous opportunity for pharmaceutical companies. This group accounts for 10% of 
the total population, but is expected to grow to 30% within five decades (Bao, 2000).  
4.4 Threat of substitutes  
Current substitutes to foreign pharmaceutical products include generic drugs, 
generic over the counter (OTC) drugs, and traditional Chinese medicine. These 
substitutes create a high threat for MNCs. In 2007, traditional Chinese medicine (TCM) 
generated sales revenue of approximately US $21 billion in China.  These traditional 
Chinese medicines represent about two-thirds of drug sales in China (PWC, 2009). This 
widespread use TCM poses as a threat and a significant competition to the conventional 
drug industry. It is forecasted that TCM sales will reach US $28 billion by 2010 (PWC, 
2009). The traditional medicine market is quite fragmented with 10 of the major 
producers accounting for only 14% of the market. Many of the larger producers are state 
owned (PWC, 2009). The TCM market faces numerous challenges that can act as an 
opportunity for pharmaceutical MNCs. TCM producers are struggling with 
inconsistencies in the manufacturing process of their products. Although the Chinese 
State Food and Drug Administration (SFDA) has enforced the Good Manufacturing 
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Practice (GMP) on these producers, there remains widespread corruption that has 
undermined the effectiveness of the certification and the products being produced (PWC, 
2009). Up until January 2009, only one third or 300 out of the 1100 traditional Chinese 
medicine manufacturers have been able to comply with the new GMP guidelines. The 
reason for such low numbers is that the manufacturers cannot acquire the necessary 
capital needed to improve manufacturing controls, productions methods, and be able to 
follow the stringent certification process (PWC, 2009).  
 
There is an opportunity for Western dugs to erode the TCM market. People are 
becoming increasingly aware that Western medicines are more effective for treating 
infectious diseases and illnesses (PWC, 2004). A study performed in 2007 found that 
Chinese consumers overall tend to prefer the traditional Chinese medicines. However, 
Western drugs were sought by these consumers when they were certain of what their 
illnesses were or wanted quick alleviation from their symptoms (PWC, 2009). Those 
pharmaceutical companies that will benefit from this trend will have drugs and treatments 
in place to help with chronic diseases (PWC, 2004).  
 
China’s over the counter (OTC) market is approximately valued at US $7.45 
billion as of 2007. This accounts for 22% of China’s pharmaceutical market, while 64% 
of the market is for generic drugs and the remaining 14% is for patented drugs.  This 
excludes traditional Chinese medicines (PWC, 2009).  PWC (2009) estimates that the 
market for over-the-counter drugs will increase to US $21.49 billion by 2012 as Chinese 
patients choose OTC drugs at pharmacies instead of the prescription drugs administered 
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at hospitals. In 2005, the Chinese government approved the use of the Internet for 
purchasing drugs within China. This approval has helped drive growth in the OTC market 
even though traditional sales channels, such as pharmacies, still dominate (PWC, 2009). 
The people prefer to purchase drugs from pharmacies where they can see the product and 
discuss the product with pharmacists. However, Internet purchasing of drugs has added to 
the problem of counterfeit trafficking thereby making it easy for fake medicines to enter 
the market.   
 
Growth in the OTC market has not translated into profit for all the manufacturers. 
The rising number of competitors is forcing manufacturers to compete over pricing, 
thereby reducing their profit margins. This in turn has hurt the smaller producers as they 
are left with little profit to reinvest into new capital needed for growth. Larger 
manufacturers that are capable of leveraging their scale have been less affected and are 
continuing the trend of expansion through mergers and acquisitions (PWC, 2009).  
 
Imported drugs and OTC drugs produced by MNCs now have the same status as 
locally made OTC drugs in terms of registration, reimbursement, and pricing (PWC, 
2006). However, these foreign OTC drugs retail for three to four times more than locally 
produced drugs and thus narrow the consumer market (PWC, 2006). The OTC products 
may reduce MNC revenues in China in the short term; however, they serve to build brand 
awareness.  
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4.5 Bargaining power of suppliers 
The bargaining power for the chemical producers and raw materials producers is 
increasing from low levels throughout China as the need for quality products for 
manufacturing is growing.  With China’s government enforcing the GMP regulations, 
many of the smaller wholesalers for chemical products and materials have been shutdown 
due to being unqualified and lacking necessary capital.  Larger corporations that have 
economies of scale are now becoming capable of setting prices for manufacturers. A key 
success factor for foreign pharmaceutical corporations would be a thorough 
understanding of the supply network and competencies for sourcing active ingredients. 
However, raw materials suppliers are not the only ones gaining power. The market for 
outsourcing to China is growing and contract research organizations (CROs) and contract 
manufacturing organizations (CMOs) are becoming the new suppliers for foreign 
pharmaceutical MNCs looking to outsource work to achieve lower costs and increased 
profits. The need to expand into China remains the objective for many pharmaceutical 
MNCs but, during hard economic times, more MNCs are looking to outsource instead of 
starting their own operations.  
 
Western pharmaceutical companies face increased research and development 
costs, shorter cost recovery times, and decreasing drug applications and approvals (PWC, 
2009). Western pharmaceuticals need to find solutions for securing long-term 
profitability. China’s strong economy has helped the country become a strong R&D 
outsourcing destination for foreign pharmaceutical MNCs (PWC, 2006). Pharmaceutical 
MNCs are looking to China’s strong R&D market to help reduce their products’ time and 
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cost to market. This has lead to an increase in the number of contract research 
organizations (CROs) in China. These CROs cost significantly less than the Western 
based CROs; at the same time, these Chinese CROs have shown their ability to meet 
Western guidelines and standards for drug quality and safety (PWC, 2009). The Chinese 
CROs are not limited to chemistry-based research; they are now moving into genomics 
and gene therapy, while simultaneously offering services such as Good Laboratory 
Practice (GLP) level preclinical outsourcing and full scale clinical trials (PWC, 2009).  
 
Western pharmaceutical MNC suppliers for clinical research and R&D are using 
the Chinese CROs increasingly. A number of factors are increasing the bargaining power 
of these CROs, such as their cost, timesavings, large talent pool, large patient pool, 
animal resources for animal testing, and a tremendous number of affluent Chinese people 
in need of diabetic, cancer, and cardiovascular drug development. China’s low cost base 
offers significant savings in labour and laboratory set-up costs.  China also offers strong 
government incentive programs such as tax holidays, tax cuts, and value added tax 
exemptions (PWC, 2009). China offers a large pool of talent in the sciences, including 
Western-educated Chinese returning to work in China. In 2006, the reported number of 
Chinese graduates in the field of chemistry and pharmaceuticals reached over 39,000 and 
22,000 respectively. The patient pool in the country is composed of a large number of 
people who are unable to afford treatment and are willing to undergo testing, thereby 
enabling easy and cost-effective patient recruitment (PWC, 2009). Animal testing 
conducted in China helps Western pharmaceutical MNCs save money on transportation 
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and quarantine expenses.  In addition to this, most of the animals needed for testing are 
normally imported from China.  
 
With several hundred CROs currently operating in China, the CRO market is 
highly fragmented. There is an increasing number of domestic CROs that are emerging as 
one-stop service providers that have the capability of offering numerous services along 
the value chain from drug discovery to registration and marketing (PWC, 2009).  The 
increasing competency of these organizations raises their bargaining power over 
pharmaceutical corporations both domestic and foreign.  
 
Bargaining power for the contract research organizations is growing steadily 
along with the bargaining power for contract manufacturing organizations (CMOs). 
CMOs in China enable the large pharmaceutical MNCs to protect their bottom line– 
profit margin. These Chinese CMOs provide significant cost advantages for foreign 
pharmaceuticals who are seeking ways to reduce cost, have growth potential, provide 
flexible capacity, and improve time to market (PWC, 2009). China is ranked the best 
country for pharmaceutical outsourcing over other Asian territories including India, 
Singapore, Japan, Korea, Taiwan, and Malaysia. In 2007, the export value of China’s 
CMOs was valued at US $453 million with an annual growth rate of 23% (PWC, 2009). 
China’s CMOs adhere to the Chinese GMP regulations that were based on concepts 
similar to the US Good Manufacturing Practices. With an increased commitment to 
international standards, Chinese CMOs are securing more orders that are international 
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from large pharmaceutical MNCs, such as AstraZeneca that spends US $9 billion a year 
on purchasing from CMOs.  
4.6 Rivalry within the environment   
The first multinational companies to enter China in the mid 1980s established 
manufacturing, sales, and marketing branches (Brueckner, 2005). These companies came 
from Japan, United States, and Europe, and either formed joint ventures with Chinese 
companies (e.g. Xian-Janssen) or established wholly owned subsidiaries (e.g. Roche). 
The Chinese pharmaceutical environment is becoming increasingly competitive as 
smaller domestic firms are exiting the market due to their inability to comply with GMP 
regulations.  According to Brueckner (2005), the true challenge of MNCs is not how to 
become profitable in China, but how to sustain a strong market position. He argues that 
China’s growth and competition requires every market leader to continually reinvest their 
profits to maintain market share with the high level of rivalry that exists.  
Chinese drug producers have significant market offerings. These producers have 
an enormous pool of workers, provide flexible working conditions, and provide an 
average hourly pay of US $0.50.  These wages are lower than Mexico’s US $2.30 and 
India’s US $0.80 (Festel, et al., 2005). In addition, Chinese producers have access to raw 
and processed materials that meet global quality standards and these materials cost 20% 
to 40% less than comparable products sold on established markets.  
Competition in the domestic OTC drug market is expected to increase as more 
MNCs and global players attempt to break into the OTC market. Positioned in this 
market are a number of MNCs, including large corporations such as GlaxoSmithKline, 
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Johnson & Johnson, and Novartis (Brueckner, 2005). Both domestic and foreign OTC 
manufacturers are aggressively marketing their goods and increasing brand awareness in 
order for consumers to distinguish their products (PWC, 2009). In order for foreign or 
domestic OTC manufacturers to make their products stand out from one another there 
needs to be an increase in product quality, packaging design improvements, and increased 
access to better distribution channels.  
Domestic Chinese pharmaceutical companies are spending more money on 
improving their research and development sectors in an attempt to move up the value 
chain. Zhejiang Huahai Pharmaceutical Co. Ltd. achieved a breakthrough in 2007 by 
getting US FDA approval for its Abbreviated New Drug Application (ANDA) for 
nevirapine tablets. This marked the first time that a Chinese pharmaceutical company had 
received US FDA certification for a finished (formulated) drug (PWC, 2009).   
4.7 Summary  
Pharmaceutical corporations wanting to expand into China should consider the 
forces analyzed in this chapter. These forces include the threat of entry (high but 
dropping), bargaining power of buyers (low), threat of substitutes (high), bargaining 
power of suppliers (low but rising), and competitive rivalry (high). Some of the key 
success factors to establish business in China’s pharmaceutical market would be to utilize 
the complex distribution channels effectively to reach the consumer, sourcing of active 
ingredients, and production/selling of generic and proprietary drugs. Other KSFs would 
be to find ways to protect intellectual property from infringements; understanding pricing 
controls and pressures by the government, hospitals and consumers; to improve the 
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underdeveloped retail options; and to gain a clear understanding of the market and 
regulatory landscape.   
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5: Recommendations 
Multi-national corporations interested in investing in China’s pharmaceutical 
industry will encounter many differences compared to establishing a business in North 
America.  This chapter explores the key success factors for doing business in China.  In 
particular, it will examine organizational behaviour and competencies.  Chronic disease 
prevention is also discussed. 
5.1 Key success factors for doing business in China 
Pharmaceutical multinationals looking to invest into China via mergers, 
acquisitions, or joint ventures should consider the key success factors (KSFs) of doing 
business in China as outlined by Abramson and Ai (1999). These authors identified four 
key success factors.  The first and most important is building a guanxi relationship based 
on shared goals and trust.  The guanxi relationship avoids transactional relationships 
based on competition for positive outcomes. The second KSF is having the experience to 
understand and deal with uncertainties that would arise in Chinese business. The third 
KSF is the informal coordinating of interaction patterns with the relevant Chinese so that 
information is shared easily and informally. The fourth most important KSF would be 
local investment in China through value chain activity transfer (Abramson & Ai, 1999).  
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The building of guanxi, or good connections, can lead to sustained and 
competitive advantages while working in China. However, guanxi has to be valuable, 
rare, and imperfectly imitable before it can lead to a sustainable advantage (Tsang, 1998). 
Even if an advantage is gained, sustaining guanxi can be difficult because it can be easily 
disrupted by a simple conflict.  A study performed by Abramson and Ai found Chinese 
managers mentioning that having guanxi relationships was a source of success for doing 
business in China. However, developing shared goals implies that both sides respond to 
each other’s needs and that both sides develop a platform of interdependent goals that can 
only be achieved by working together (Abramson & Ai, 1999).   
 
Experience and continuous awareness of and adaption to the changing Chinese 
business environment are important for pharmaceutical MNCs to be aware of while 
conducting business in China. Experience in other international markets has value; a 
more general international experience and the knowledge gained from them can be 
applied to doing business in China.  Abramson & Ai (1999) found that companies that 
have a stronger perception of uncertainty and a greater need to vary marketing strategies 
as a response to environmental change had higher performance and sales in China.  
 
Foreign MNCs managers should reconsider how they rely upon the expertise from 
their local Chinese experts for ways of conducting business. According to Abramson & 
Ai (1999), the usage of formal group processes, meetings, problem solving groups, 
policies, procedures, and schedules may not be an effective means for gathering 
information.  There is Chinese reluctance, which is based on Confucian hierarchal values, 
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to challenge the thoughts and opinions of those higher up the chain of command. These 
local Chinese experts are more comfortable and willing to provide information on an 
informal basis with those whom they have built a more trusting relationship.  
 
Local investment by transferring through value chain activity may produce more 
customer value by adapting products to local Chinese conditions (Abramson & Ai, 1999). 
Research conducted by Abramson and Ai (1999) found that companies transferring R&D, 
sourcing, and manufacturing may not obtain significant advantages by investing locally; 
however, Chinese managers interviewed emphasized the importance of local investment 
and the need for foreign companies to transfer value chain activities. The research 
suggested that local investment is needed to close the gap between the companies and the 
customers by providing locally oriented and available marketing, sales, and service.   
 
These key success factors are essential for successful operations in the Chinese 
pharmaceutical market.  This is addition to the ones identified in Chapter 4.  These 
include utilizing the complex distribution channels to reach the consumers, sourcing of 
active ingredients, production and selling of generic and proprietary drugs, finding ways 
to protect themselves from intellectual property infringements and pricing controls or 
pressures, improving the underdeveloped retail options, and gaining a clear understanding 
of the market and regulatory landscape.   
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5.1.1 Organizational Behaviour and Competencies 
Pharmaceutical corporations expanding into China should consider external 
environmental conditions along with their internal capabilities. A few key internal factors 
for success in China include managerial persistence, financial resources, and permanent 
learning and adaption (Yau, 2000). Managerial persistence in China’s pharmaceutical 
market can create a competitive advantage. According to Bruche (1996), this advantage 
can only be created if local managers in China are backed up by an understanding 
headquarters that works on the assumption that local conditions are better understood by 
local managers. Management can achieve persistence via a selection of expatriate 
managers that are capable of taking on hardships associated with the positions over an 
extended period. In addition, companies should have an effective means for rotating 
expatriates to ensure that persistence based on growing know how is maintained (Yau, 
2000). Companies should have incentives and policies in place to help nurture a core of 
open minded, capable, and loyal Chinese managers in order to maintain a competitive 
advantage in the pharmaceutical market (Yau, 2000). Investing in foreign countries also 
requires a high degree of adaptability.  Companies need to be able to unlearn routines that 
were created to meet environmental situations that are now outdated (Yau, 2000). 
Research conducted by Bruche (1996) found that companies might be more successful by 
having a soft organizational structure that is able to cope with emerging new 
environments and make quick changes without disrupting operations.  
 
Companies already established in China’s pharmaceutical market face tremendous 
pressures from followers that are now entering. In order to maintain a competitive 
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advantage early movers into China need to protect their assets and use their assets to 
create advantage.  Managerial personnel are one of the key internal assets these 
companies have and their knowledge and proprietary information must be retained within 
the company. Leveraging assets to create more products or deepening the outreach to 
more customers through established logistics can help reduce the threat of competitors 
(Yau, 2000).  
 
Those pharmaceuticals that are followers into China’s market need to take on a 
more offensive strategic posture. They can try through obtaining managers already 
trained by the first movers to help establish their new company. They can also try to 
exploit weaknesses of early movers such as lack of adaptability or try to penetrate less 
competitive areas either product wise or region wise (Yau, 2000). The most important 
consideration stated by Bruche (1996) for new comers into a market would be product 
positioning and demonstrating the benefits and effectiveness of their products over 
existing pharmaceutical products already established in the market.  
5.2 Chronic disease prevention 
Many countries throughout the world are dealing with the rising epidemic of 
chronic diseases. Implementation of a stepwise framework for preventing chronic disease 
offers a practical approach for ministries of health in balancing diverse needs and 
priorities while conducting evidence based interventions (Beaglehole et al., 2005). The 
framework focuses on a public health approach to chronic disease prevention. According 
to Beaglehole et al. (2005), the first step requires the national level of government to 
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provide the basic framework for chronic disease prevention and control so that actions at 
all levels by all stakeholders are mutually supportive. Next, intersectoral action is need at 
all stages of policymaking and implementation because major determinants of chronic 
disease lie outside the health sector. Policies and plans must focus on the common risk 
factors and cut across specific diseases, while population wide and individual 
interventions need to be combined (Beaglehole et al., 2005). For those countries that do 
not have the resources to immediately do everything implied by the overall policy, 
Beaglehole et al. (2005), recommends that activities that are feasible and likely to have 
greatest impact should be selected first for implementation. The programs needed for 
implementation should be categorized as interventions that are core, expanded, or 
optimum – based on availability of resources and political and community support 
(Leeder et al., 2007).  Lastly, locally relevant and explicit milestones should be set for 
each step at each level of intervention with the main focus on reducing health inequalities 
(Beaglehole et al., 2005).  
 
In China’s case, prevention is the best and most important strategy to be 
implementing. Reduction in behavioural risk factors alone could generate substantial 
health benefits (Koplan et al., 2008). China needs to prioritize prevention strategies such 
as tobacco reduction, awareness of exposure to second hand smoke, education on the 
dangers of high dietary intakes of salt and fat, and promotion of increased physical 
activity. These prevention strategies cannot be isolated from other sectors such as 
employment, income maintenance, social welfare, housing, education, and mass media 
(Koplan et al., 2008). According to the research conducted by Koplan et al. (2008), 
  
68 
undertaking prevention activities in China will require strengthening of the existing 
health prevention and disease control systems. Institutional reforms will have to be 
realigned to establish strategies for controlling chronic diseases. Social action will be one 
of the major strategies for reducing non-communicable diseases. Koplan et al. (2008), 
argues that reducing non-communicable diseases is the key intervention for reduction of 
poverty, and the reduction of social inequalities and inequities in health. They believe 
that social actions need to include mobilisation of allied sectors, including transport, 
education, fiscal policy, regulatory action, and urban design. Transport will address the 
growth in automobile use and less friendly environments for cycling and pedestrians; 
education will enhance comprehensive school-based health education and promotion; 
fiscal policy will increase tobacco taxes; regulatory action will ensure food safety and 
content, and prohibit smoking in public places; and urban design can provide parks, green 
spaces and paths for bicycles and walkers.    
 
China’s Ministry of Health should develop more broad capabilities and skills. It 
should create a national campaign for the reduction of salt intake, including dietary 
guidelines and food labelling (Koplan et al., 2008). People should have blood pressure 
monitored and measured during healthcare encounters and in non-traditional areas such 
as shopping areas and recreational sites. Some of China’s successful projects included the 
use of cancer registries, which allowed the government to focus on areas of high 
prevalence. Cancer registries led to the institution of the Program of Cancer Prevention 
and Control in China. Other community based intervention programs focused on diabetes 
and hypertension control have helped reduce the number of stroke victims (Burton et al., 
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2005). The Ministry of Health has established more than 32 community based sites that 
diagnose, train, and help in developing intervention programs for combating 
cardiovascular disease, hypertension, mental health, cancer, and other chronic diseases 
(Burton et al., 2005).  
 
Intervention programs at schools can also play a large part in the prevention of 
chronic diseases.  Chang et al. (2004) conducted a pilot project in the Zhejiang Province 
of China to create a health-promoting school program aimed at improving the nutrition 
and health status of students, school personnel, and parents. Their research found that a 
coordinated intervention of nutritional education in the classroom, changes to school 
policies, school environment, school-based health and nutrition services, and active 
outreach to family and community members resulted in an a significant improvement in 
nutrition-related attitudes, knowledge gains, and hygienic habits (Chang et al., (2004). 
However, Chang et al. (2004) found that schools alone could not meet the need for 
increased nutrition, information, and education.  These schools, they believed, needed 
help from institutions such as the health sector, medical corporations, and pharmaceutical 
corporations for funding and support. A vast majority of the activities undertaken in this 
pilot project were extracurricular. Although they were valuable and effective and can 
have dramatic effects on China’s health care system, establishing nutrition and health 
education on a regular basis in schools remains an important objective (Chang et al., 
2004).  
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On January 21, 2009, the Ministry of Health of China outlined five areas of 
reform for the healthcare system in the coming years: 
• Expansion of basic medical insurance programs to enrol more than 90% of urban and 
rural residents 
• Establishing a national drug system for essential drug selection, production, supply, 
clinical applications, and medical insurance reimbursements 
• Building a competent primary medical care service infrastructure in rural township 
centres, village clinics and urban community healthcare centres 
• Enhancing equal access to basic public health services by urban and rural residents 
• Moving public hospital reform forward: this includes reform for the funding of 
hospitals, which is now predominantly based on sales of drugs and diagnostic 
examination fees (PWC, 2009) 
5.3 Summary  
Investing in China’s pharmaceutical industry through mergers, acquisitions, or 
joint ventures requires MNCs to consider key success factors (KSFs) of doing business in 
China. These KSFs include building a guanxi relationship based on shared goals, 
avoiding transactional relationships based on competition, having the experience to 
understand and deal with uncertainties, coordinating interaction patterns for information 
sharing, and local investment in China through value chain activity transfers. 
 
Pharmaceutical corporations expanding into China should consider external 
environmental conditions along with their internal capabilities. A few key internal factors 
  
71 
for success in China include managerial persistence, financial resources, and permanent 
learning and adaption. 
 
Implementation of a stepwise framework for preventing chronic diseases offers a 
practical approach for ministries of health in balancing diverse needs and priorities while 
conducting evidence-based interventions. The framework focuses on a public health 
approach to chronic disease prevention.   
 
Prevention is an important strategy that the Chinese government needs to focus on 
in order to reduce the rising number of people with chronic diseases. Reduction in 
behavioural risk factors could generate substantial health benefits. Creating health-
promoting school programs aimed at improving the nutrition and health status of 
students, school personnel, and parents is imperative for the reduction of chronic 
diseases. Coordinated intervention of nutritional education in the classroom, active 
outreach to family and community members, and changes to school policies and services 
can significantly improve nutritional-related attitudes, knowledge gains, and hygienic 
habits in China.  
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6: Conclusion 
Chronic diseases can also be referred to as non-communicable diseases to 
differentiate it from communicable diseases that are infectious.  In treating chronic 
diseases, a national economy is impacted by the direct costs of medical care, the indirect 
costs through loss of human resources and productivity, and the intangible costs through 
psychological ailment. Together, these different costs lead to reduced earning potential 
among families and reduced national gross domestic product.  This places a particular 
strain on developing countries that must decide between increasing economic wealth or 
alleviating social, economic, and health deficiencies. 
 
 In China, urbanization, an ageing population, and an improved standard of living 
have resulted in an increase in chronic diseases.  Physical activity has decreased, while 
the diet has gravitated towards a Westernized high fat, low nutrition diet.  Urbanized 
areas with higher incomes have been most noticeably afflicted with hypertension, 
obesity, diabetes, and tobacco addictions.  However, rural areas have also seen an 
increase in chronic diseases as their diets and lifestyles are changing as well. 
 
 Unfortunately, China’s health care system is decentralized and fragmented.  It is 
not well suited to making a rapid coordinated response to public health emergencies.  In 
addition to this, there is a disproportionate percentage of government spending on health 
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care compared to the vast proliferation of chronic diseases.  Many residents lack health 
insurance and cannot afford medical care.  Treatments for chronic diseases can cost up to 
half the annual salary of urban residents or three times the annual income of rural 
residents.  This is partially due to the commercial relationship between pharmaceutical 
companies and medical drug distributors, such as hospitals.  The pursuit of wealth by 
these companies and the distributors drives up the cost of pharmaceuticals for patients to 
the point where it is unattainable.  This makes China ill equipped to detect and control 
epidemics as diseased individuals often go undiagnosed and untreated.    
 
 The inadequacies of the health care system in China lend many opportunities for 
pharmaceutical multinational corporations.  Threat of entry is high, but dropping; 
bargaining power of buyers is low; threat of substitutes is high; bargaining power of 
suppliers is low, but rising; and competitive rivalry is high.  Key success factors are to 
use the complex distribution system to reach the consumer, the sourcing of active 
ingredients, and the production and selling of generic and proprietary drugs.  
Pharmaceutical corporations trying to establish operations in China should also consider 
ways to protect intellectual property from infringement, understand pricing controls and 
pressures, improve the underdeveloped retail options, and gain an understanding of the 
market and regulatory landscape. 
  
  Future recommendations for China are to implement a stepwise framework for 
preventing chronic disease. Reduction in behavioural risk factors is crucial to generating 
substantial health benefits.  Additionally, school programs that educate students, staff, 
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and parents on how to improve their nutrition and health can create awareness and long-
term benefits towards the reduction of future chronic diseases.  The health sector, medical 
corporations, and pharmaceutical corporations can also play a large part in terms of 
funding and support for these educational programs. 
 
The rise of chronic diseases is not isolated to China; India and other developing 
countries are on pace of reaching epidemic levels.  The number of people in need of 
healthcare, education regarding diet and healthiness, and pharmaceutical drugs is 
increasing.  Despite the challenges, foreign MNC’s pharmaceutical prospects for growth 
and profitability are immense. China and now India have the capability of becoming the 
world’s largest pharmaceutical markets, boasting low development and manufacturing 
costs while offering increased opportunities for R&D and clinical trials.  
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